With eyes on an IPF franchise, Galapagos pushes second candidate into a dose-finding study
While the proof-of-concept results for Galapagos’ second idiopathic pulmonary fibrosis candidate didn’t turn up quite as much excitement as its lead candidate, the Belgian biotech says it’s enough to push forward with a dose-finding study.
The Phase II study assessed GLPG1205 in 68 IPF patients over 26 weeks. Volunteers were allowed to continue their standard of care, including nintedanib and pirfenidone. While the early study “was not powered to show statistical significance,” according to the company, those in the treatment arm showed a smaller forced vital capacity (FVC) decline from baseline than those on a placebo — 34 mL, compared to 76 mL in the placebo arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.